SANA(SANA)
SANA
Signal
Bearish Setup2↓
PRICE
Prev Close
3.14
Open
3.05
Day Range2.96 – 3.11
2.96
3.11
52W Range1.63 – 6.55
1.63
6.55
29% of range
VOLUME & SIZE
Avg Volume
3.4M
FUNDAMENTALS
P/E Ratio
-3.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
2.24
High vol
Next earnings: Aug 10, 2026
ANALYST COVERAGE11 analysts
BUY
▲ +128.0%upside to target
L $7.00
Med $7.00consensus
H $12.00Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 92 days
Aug 17
Key MetricsTTM
Market Cap$854.36M
Revenue TTM$0.00
Net Income TTM-$241.99M
Free Cash Flow-$133.64M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-161.9%
Return on Assets-64.8%
Debt / Equity0.63
Current Ratio1.29
EPS TTM$-0.87
SANA News
About
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly available to patients. Sana is more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
Industry
Research and Development in Biotechnology
Website
Dhavalkumar D. PatelExecutive Vice President & Chief Scientific Officer
Gary MeiningerChief Medical Officer
Steven D. HarrPresident, Chief Executive Officer & Director
Yuko SoneokaHead of Intellectual Property
Aaron GrossmanExecutive VP, Chief Legal Officer & Corporate Secretary
Brian D. PiperExecutive Vice President & Chief Financial Officer
John GerecitanoHead of Oncology Research & Development
Snehal PatelSenior Vice President & Chief Technical Officer
Debra WisdomVP & Head of People
Susan WyrickTreasurer, Principal Accounting Officer and Senior VP of Finance & Accounting